Working… Menu
Trial record 1 of 2 for:    xencor | Recruiting Studies | Hematological Malignancy
Previous Study | Return to List | Next Study

Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02924402
Recruitment Status : Recruiting
First Posted : October 5, 2016
Last Update Posted : March 25, 2021
ICON Clinical Research
Information provided by (Responsible Party):
Xencor, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : October 2025